{"ticker": {"uuid": "8b8cc642-9ee2-4e96-b397-39546c14a441", "symbol": "MREO", "name": "Mereo BioPharma Group PLC ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mereo BioPharma (MREO) Stock Edges Higher as Biotech Names Find Mixed Footing - Bear Pennant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOYldqTVMyS0dHVUxaQjh0VVJwZVRLNzNqSGM1R0toQkxtNXhFdmhuSXY2SVBHQ285YzVDemNDUkhZaUhVZGd3TldjS2djUmthdnh1eTQ3QVpWX19kb2szZlhJM3BuMFg5QUlwRExnRTlHZnNfSDBsaVdlMml6a0hLS0dHOTFuS2Npay1Pcm1kZ1lBcUIyb2RscXJuZmJTZEplWEZpclU0V3NFWkItMElHTXAzclR0U3kzd2NPRmxIakNDR0E?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-12T19:48:07+00:00", "published_display": "12 Jul 2026 19:48", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5DQk8zTHNGSE4yVGNGa2hLa2dibUZ3eENXSXk3NmdWTG1GNlltYTFaUVYwV3N2b1RNb3JXdmdHQVpTWW9JSUI4Vy0wLUdVTUlVVDhVQ3I3bWtlNXV6Q0tDSm51Sjc?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:19:32+00:00", "published_display": "11 Jul 2026 00:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC (MREO) Institutional Confidence", "summary": "The article discusses the institutional confidence score for Mereo BioPharma Group PLC (MREO), which is currently 3.00, ranking 192 out of 386 in its industry. The institutional shareholding proportion has decreased by 38.82% quarter-over-quarter, with James Simons being the larg", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mreo/sentiment", "source_name": "TradingKey", "published_at": "2026-07-10T19:39:39", "published_display": "10 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MREO Stockholders Have Opportunity to Lead Mereo BioPharma Group", "summary": "A class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ:MREO) and some of its officers by Bronstein, Gewirtz & Grossman, LLC. The lawsuit alleges that Mereo BioPharma made false and misleading statements about its Phase 3 ORBIT and COSMIC programs, which d", "url": "https://natlawreview.com/press-releases/mreo-stockholders-have-opportunity-lead-mereo-biopharma-group-plc-class", "source_name": "The National Law Review", "published_at": "2026-06-30T17:10:40", "published_display": "30 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Mereo BioPharma Group plc (MREO) Investors to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Mereo BioPharma Group plc (NASDAQ:MREO) investors following a significant stock price drop. This drop occurred after Mereo announced that two Phase 3 studies for its treatment, setrusumab, failed to", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-mereo-biopharma-group-plc-mreo", "source_name": "The National Law Review", "published_at": "2026-06-27T15:11:14", "published_display": "27 Jun 2026 15:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Mereo BioPharma Group plc \u2013 NASDAQ:MREO", "summary": "This article provides financial data for Mereo BioPharma Group plc (NASDAQ: MREO), specifically focusing on its enterprise value to EBIT forward. The content is presented within the context of TradingView's platform, offering an overview of the company's financial metrics. Howeve", "url": "https://www.tradingview.com/symbols/NASDAQ-MREO/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:38:56", "published_display": "27 Jun 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Mereo BioPharma Group plc \u2013 NASDAQ:MREO", "summary": "This article focuses on the \"Price to book forward\" metric for Mereo BioPharma Group plc, traded under the ticker NASDAQ:MREO. It appears to be a stub or a section of a larger financial data presentation from TradingView, indicating specific financial metrics for the company. The", "url": "https://www.tradingview.com/symbols/NASDAQ-MREO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T07:40:53", "published_display": "26 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Mereo BioPharma Group plc \u2013 NASDAQ:MREO", "summary": "The article focuses on the \"Price to earnings forward\" metric for Mereo BioPharma Group plc (NASDAQ: MREO). It notes that the market is currently closed with no trades, and the content primarily comprises extraneous website navigation and copyright information for TradingView and", "url": "https://www.tradingview.com/symbols/NASDAQ-MREO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T06:11:12", "published_display": "25 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC (MREO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Mereo BioPharma Group PLC (MREO), assessing its profitability and balance sheet. The company has a robust financial status with a score of 7.61, ranking 100 out of 389 in its industry, although its operating efficiency is noted as low", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mreo/financial-health", "source_name": "TradingKey", "published_at": "2026-06-22T12:10:40", "published_display": "22 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC (MREO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Mereo BioPharma Group PLC (MREO), indicating its current valuation score is 7.17 within the Biotechnology & Medical Research industry. It details the company's valuation metrics, including a P/E ratio of -1.39, while noting that relev", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mreo/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:41", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC (MREO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Mereo BioPharma Group PLC (MREO), detailing its current price momentum score, support and resistance levels, and indicator readings. It includes signals from various technical indicators like MACD, RSI, and moving averages, suggesting", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mreo/technical", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:41", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC (MREO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Mereo BioPharma Group PLC (MREO), indicating a strong earnings forecast score and a positive analyst rating. It details the average price target, expected revenue for the next quarter, and historical EPS performance. The report highl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mreo/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:41", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC (MREO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Mereo BioPharma Group PLC (MREO). It indicates that Mereo BioPharma has not distributed any dividends over the past five years and has no recorded stock split history. The page also presents current stock pri", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mreo/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T22:11:26", "published_display": "17 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma : to Participate in Fireside Chat at the Jefferies Global Healthcare Conference 2026", "summary": "Mereo BioPharma Group plc will participate in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 4, 2026, featuring CEO Dr. Denise Scots-Knight. The clinical-stage biopharmaceutical company focuses on rare diseases and has product candidates for osteogenes", "url": "https://www.marketscreener.com/news/mereo-biopharma-to-participate-in-fireside-chat-at-the-jefferies-global-healthcare-conference-2026-ce7f5ddfde8ff12d", "source_name": "www.marketscreener.com", "published_at": "2026-06-03T14:47:00", "published_display": "03 Jun 2026 14:47", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MREO - Mereo Biopharma Group Plc ADR Stock Price and Quote", "summary": "This article provides comprehensive financial data and news for Mereo Biopharma Group Plc ADR (MREO), including its latest stock performance, key financial metrics, analyst ratings, and a chronological list of corporate news and press releases. The company is actively developing ", "url": "https://finviz.com/stock?t=MREO", "source_name": "Finviz", "published_at": "2026-05-30T02:39:37", "published_display": "30 May 2026 02:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo Biopharma Group plc Announces Termination of Dr Annalisa Jenkins from Director, Effective May 14, 2026", "summary": "Mereo Biopharma Group plc has announced that Dr. Annalisa Jenkins's appointment as a director was terminated, effective May 14, 2026. This information was reported by S&P Capital IQ. The company's stock, MREO, saw a minor dip of 0.29% on the day of the announcement, though it had", "url": "https://www.marketscreener.com/news/mereo-biopharma-group-plc-announces-termination-of-dr-annalisa-jenkins-from-director-effective-may-ce7f5dd8db8bf125", "source_name": "www.marketscreener.com", "published_at": "2026-05-26T01:09:55", "published_display": "26 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group plc (NASDAQ: MREO) Long Term Investor Alert: Investigation of potential Wrongdoing", "summary": "A law firm has announced an investigation into potential breaches of fiduciary duties by directors and officers of Mereo BioPharma Group plc (NASDAQ: MREO) on behalf of current long-term investors. This follows a lawsuit alleging securities law violations related to overselling t", "url": "https://www.openpr.com/news/4520764/mereo-biopharma-group-plc-nasdaq-mreo-long-term-investor", "source_name": "openPR.com", "published_at": "2026-05-20T20:09:19", "published_display": "20 May 2026 20:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EcoR1, Oleg Nodelman report 8.4% stake in Mereo (MREO)", "summary": "EcoR1 Capital, LLC and Oleg Nodelman have jointly reported an 8.4% beneficial ownership stake in Mereo BioPharma Group plc (MREO) through an amended Schedule 13G/A filing. This includes shared voting and dispositive power over 66,844,275 Ordinary Shares, which are held via Americ", "url": "https://www.stocktitan.net/sec-filings/MREO/schedule-13g-a-mereo-bio-pharma-group-plc-amended-passive-investment--1664f3adff80.html", "source_name": "Stock Titan", "published_at": "2026-05-15T18:26:06", "published_display": "15 May 2026 18:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bank of America reports 5.1% stake in Mereo BioPharma | MREO SEC Filing - Form SCHEDULE 13G", "summary": "Bank of America Corporation has reported a 5.1% beneficial ownership stake in Mereo BioPharma Group plc (MREO), amounting to 40,976,460 ordinary shares. This disclosure was made via a SCHEDULE 13G SEC filing, indicating shared voting and dispositive power across Bank of America a", "url": "https://www.stocktitan.net/sec-filings/MREO/schedule-13g-mereo-bio-pharma-group-plc-passive-investment-disclosure-9d4596797fee.html", "source_name": "Stock Titan", "published_at": "2026-05-14T18:40:35", "published_display": "14 May 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Shareholders Approve All AGM Resolutions", "summary": "Mereo BioPharma Group plc shareholders approved all proposed resolutions at their Annual General Meeting on May 14, 2026. Key approvals included the 2025 annual report, auditor reappointment, executive pay, director reappointments, and the extension of share issuance authorities ", "url": "https://www.tipranks.com/news/company-announcements/mereo-biopharma-shareholders-approve-all-agm-resolutions", "source_name": "TipRanks", "published_at": "2026-05-14T15:39:13", "published_display": "14 May 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma shareholders approve all resolutions at annual meeting", "summary": "Mereo BioPharma Group plc announced that all resolutions were approved at its 2026 Annual General Meeting of Shareholders. This included the adoption of the annual report, re-appointment of PwC as auditors, approval of directors' remuneration and policy, and the re-appointment of", "url": "https://m.investing.com/news/sec-filings/mereo-biopharma-shareholders-approve-all-resolutions-at-annual-meeting-93CH-4689130?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-14T14:40:35", "published_display": "14 May 2026 14:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma (NASDAQ: MREO) gains investor approval for pay and share issuance powers", "summary": "Mereo BioPharma Group plc shareholders approved all resolutions at their 2026 Annual General Meeting, including the 2025 accounts, re-appointment of auditors PwC, director remuneration reports and policies, and the re-election of three directors. Investors also authorized the dir", "url": "https://www.stocktitan.net/sec-filings/MREO/8-k-mereo-bio-pharma-group-plc-reports-material-event-29498cef632f.html", "source_name": "Stock Titan", "published_at": "2026-05-14T14:39:13", "published_display": "14 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo Biopharma (MREO) Stock News & Updates", "summary": "This page provides news and updates for Mereo Biopharma (MREO), focusing on its rare-disease biopharmaceutical pipeline. Recent reports highlight financial results, clinical trial progress for setrusumab, alvelestat, and vantictumab, including successes in bone mineral density an", "url": "https://www.stocktitan.net/news/MREO/", "source_name": "Stock Titan", "published_at": "2026-05-14T09:10:24", "published_display": "14 May 2026 09:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO", "summary": "Pomerantz LLP has filed a class action lawsuit against Mereo BioPharma Group plc (MREO) on behalf of investors who suffered losses. The lawsuit alleges securities fraud following significant drops in Mereo's ADR price after clinical trial results for UX143 (setrusumab) failed to ", "url": "https://www.easternprogress.com/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-mereo-biopharma/article_9286c583-e440-5c06-bb53-10cc52005108.html", "source_name": "Eastern Progress", "published_at": "2026-05-14T02:10:06", "published_display": "14 May 2026 02:10", "sentiment": "negative", "sentiment_pct": 16, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates", "summary": "Mereo BioPharma reported its first quarter 2026 financial results, highlighting ongoing efforts to advance its rare disease pipeline. The company is engaging with regulatory agencies regarding setrusumab for pediatric osteogenesis imperfecta and seeking partners for alvelestat's ", "url": "https://uk.finance.yahoo.com/news/mereo-biopharma-reports-first-quarter-113000410.html", "source_name": "Market source", "published_at": "2026-05-13T06:40:35", "published_display": "13 May 2026 06:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group Releases Q1 2026 Financial Results", "summary": "Mereo BioPharma Group plc reported a narrower net loss for Q1 2026, posting -$0.01 diluted loss per share and a net loss of $6.7M. This improvement reflects the company's efforts to control expenses while advancing its therapeutic pipeline for rare diseases. Wall Street analysts ", "url": "https://news.alphastreet.com/mereo-biopharma-group-releases-q1-2026-financial-results/", "source_name": "AlphaStreet", "published_at": "2026-05-12T13:40:03", "published_display": "12 May 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC reports results for the quarter ended March 31 - Earnings Summary", "summary": "Mereo BioPharma Group PLC has announced its earnings summary for the quarter that concluded on March 31. The report, briefly detailed by Refinitiv, provides an overview of the company's financial performance during this period.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41P1YY:0-mereo-biopharma-group-plc-reports-results-for-the-quarter-ended-march-31-earnings-summary/", "source_name": "TradingView", "published_at": "2026-05-12T13:40:03", "published_display": "12 May 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group plc 1Q 2026: Net loss $(6.7M), EPS $(0.01) \u2014 10-Q Summary", "summary": "Mereo BioPharma Group plc reported a narrower net loss of $(6.7M) in Q1 2026 compared to $(12.9M) in the prior year, with diluted EPS improving to $(0.01) from $(0.02). The company had no product revenue and is focusing on its late-stage rare disease pipeline, including setrusuma", "url": "https://www.tradingview.com/news/tradingview:6a7df2c439e4b:0-mereo-biopharma-group-plc-1q-2026-net-loss-6-7m-eps-0-01-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-12T12:40:03", "published_display": "12 May 2026 12:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma (NASDAQ: MREO) Q1 2026 loss narrows as setrusumab data mixed", "summary": "Mereo BioPharma announced its Q1 2026 financial results, reporting a narrowed net loss of $6.7 million compared to $12.9 million a year prior, primarily due to reduced general and administrative expenses. While Phase 3 trials for its key drug setrusumab in osteogenesis imperfecta", "url": "https://www.stocktitan.net/sec-filings/MREO/8-k-a-mereo-bio-pharma-group-plc-amends-material-event-report-b18d99062260.html", "source_name": "Stock Titan", "published_at": "2026-05-12T12:40:03", "published_display": "12 May 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma (NASDAQ: MREO) halves Q1 loss and outlines key trial plans", "summary": "Mereo BioPharma reported a narrower net loss of $6.7 million in Q1 2026, down from $12.9 million year-over-year, mainly due to reduced administrative expenses. The company also provided updates on its rare disease pipeline, noting that while setrusumab's Phase 3 trials missed pri", "url": "https://www.stocktitan.net/sec-filings/MREO/8-k-mereo-bio-pharma-group-plc-reports-material-event-80d130133727.html", "source_name": "Stock Titan", "published_at": "2026-05-12T11:40:03", "published_display": "12 May 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why We're Not Too Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We're Hopeful That Mereo BioPharma Group (NASDAQ:MREO) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNcm5CemI4Tmh2M2Y1R3hpd1VyRmo1MEJPVXdVdnZDaTREZTd3UG5kQ2M4VmNfOGF3b0hFWWVtaGZPMktQSVl4Z0RDMDI2eTZaQk1iMWtnVGluZTlvUnprN0p5ckpveUY1OUJSdzRXZmlhc2VBdmhURTkwckZwMjhtejM3dWtKN3RYckNRbFFLY0NsNzZDOHhOUlJPVktFZnhE?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Stockholders Who Lost Money Investing in Mereo BioPharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwJBVV95cUxOcE1Nc1dSbmx5SVhSVUk1U1BFQXlzd2VyRVczZmpMdi1HdmtMY1lJbGNlSk1jS0xMM3JsaUJ3WTlCempoSE5jaEY3WU83ZnFDOG1uMmcxTTdIMHl5TkNhSG9MZnlVUlhabm9nY0ZEMU5BeVpWTEZDbGdNS3g4OWhwaDM5MVE4M09ReGVmUWVpWm9TLXlUZW9KSGxIaWJDdmo5dnhySVM4Vjk0TXl4M1FmQ0QwcDZWX2xWT2FCZmhWOGNKWDdDdG9JdE1ESndFNHRDTjE0SFpTYjA2alJzTUFUOFZDU3d1cGoyMnVvMDA2MGJha2puQzQtNkJ3dXhKOEoyYXp0MEJEMEJjX1hkSzZ4UVNrcTBncHF4dkpmRDRyYUhicmRxWl9nR3pwNFBJcFBFM1hCa1hkUnRzSUxtY29mSldZQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Mereo BioPharma Group (MREO) Valuation After Mixed Setrusumab Phase 3 Results And Cash Runway Update", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-17T08:00:00+00:00", "published_display": "17 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group (MREO) Is Up 74.4% After Mixed Setrusumab Phase 3 Data and Cash Update \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPWUFDdHZfUGN2MFRqSWRmNG5qcFM5Zjc2bkhEOVNJMHJuZlNLbWpLMEl1b1paN3Y4eVBjNGdaWWFYLTBJQlFkc1FpSmFwNmlEWjlBNFNoU1NKZERfTkViX3RSSjkyNnd1djlLTU9ia1dWbGhwWEk2UC15Ty0xTjJ3aw?oc=5", "source_name": "Market source", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Mereo BioPharma (MREO) Is Up 69.9% After Mixed Setrusumab Phase 3 Results And Pipeline Shift", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Mereo BioPharma (MREO) Valuation After Mixed Setrusumab Phase 3 Update And Conference Spotlight", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNbVJIOHJGby05VnhZN2l6d2NvQTZOS2lfV2hpc3lMUE5tU2FTeWNPNEFNekVYbE55SGkzYlpoVUNxOWJDNjVscWRwa3dEQ2dEQlNKUDJ1bkJqTXo5aTR4OXBnZmtURU5ZTlkteXpCMTZ6VXBJdnowS0FnaTdqMVl3M2RkWlpqbmJK?oc=5", "source_name": "Market source", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group (MREO) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE1KRWZzVjJwcW9YdWlPTnRsMFZCYlJIYWJiVmtEY282UjhqZ2RjLUw1Vnk3SEFCMENMV2NxUXM2S0ZDQjhrbUVMcHRwZlFndHpidGtUU3NoWkZLYjlzQjg2X1I3QWpKWmta?oc=5", "source_name": "MarketBeat", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group Leads The Charge Among 3 Prominent Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOQmI3MG9MQTR6UVJFWWFaWVpUVWloelFpbV9sbklVb1V5ZHV1RmEyTmNCYmtmcEFNRHJnRDNXUko5d0FhZEM3eVNHa0lzc21tNVhpMV9YcVpjWFdpd0hZUk95V1NFdlVZYkxwNVVjQUNZbDJLWlBTZGR4cTFLeXVKSk83R2xFZTA?oc=5", "source_name": "Market source", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Stock (MREO) Opinions on Failed Phase 3 Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxONWh3MGJUbVBrbEREMzFmS0lsOWZvTUdJQkhESXFjbDlndHFoQ3dBbGZqdEtVNkgyODVMdDJ1ZUtzdlJ1em91SHJYeFY4VWZtVFB3QWxXcFdYQ1BZSEk5a0FLZFRrak9xYkN6Um5fT3h5YlNmOE5xUGpSQWpNZk5lOU9TVkx6ZDk1aDlJSUV5b2tjRDJ5ZGdHU0VmNUM4ZThY?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-30T08:00:00+00:00", "published_display": "30 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma stock plummets after failed Phase 3 trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPZDRNZjB0eFFfRGlwZ2xPNXIzcHY4dV9BMllZaDJRRjBIQ3VpRU8zdG9DZDI4QnRUM1hYQUpnWHQydEdkQUM2aHpIamhQVGVZVVhncUVYcG1RWWstcW9YbHFJVzY2RXlBaXdCVmxmV0xvZ1JheW91UllJTzVVTE94c1BQTXZZdS1WRGpaRGZoZjBuX1ZRaENNUWY3UndqaS1NUXJPWDkxbXA3NkNEY25jbE5Qa3M0Rk1PaTF6QQ?oc=5", "source_name": "Investing.com", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Mereo BioPharma (MREO) Stock Edges Higher as Biotech Names Find Mixed Footing - Bear Pennant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOYldqTVMyS0dHVUxaQjh0VVJwZVRLNzNqSGM1R0toQkxtNXhFdmhuSXY2SVBHQ285YzVDemNDUkhZaUhVZGd3TldjS2djUmthdnh1eTQ3QVpWX19kb2szZlhJM3BuMFg5QUlwRExnRTlHZnNfSDBsaVdlMml6a0hLS0dHOTFuS2Npay1Pcm1kZ1lBcUIyb2RscXJuZmJTZEplWEZpclU0V3NFWkItMElHTXAzclR0U3kzd2NPRmxIakNDR0E?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-12T19:48:07+00:00", "published_display": "12 Jul 2026 19:48", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5DQk8zTHNGSE4yVGNGa2hLa2dibUZ3eENXSXk3NmdWTG1GNlltYTFaUVYwV3N2b1RNb3JXdmdHQVpTWW9JSUI4Vy0wLUdVTUlVVDhVQ3I3bWtlNXV6Q0tDSm51Sjc?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:19:32+00:00", "published_display": "11 Jul 2026 00:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC (MREO) Institutional Confidence", "summary": "The article discusses the institutional confidence score for Mereo BioPharma Group PLC (MREO), which is currently 3.00, ranking 192 out of 386 in its industry. The institutional shareholding proportion has decreased by 38.82% quarter-over-quarter, with James Simons being the larg", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mreo/sentiment", "source_name": "TradingKey", "published_at": "2026-07-10T19:39:39", "published_display": "10 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MREO Stockholders Have Opportunity to Lead Mereo BioPharma Group", "summary": "A class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ:MREO) and some of its officers by Bronstein, Gewirtz & Grossman, LLC. The lawsuit alleges that Mereo BioPharma made false and misleading statements about its Phase 3 ORBIT and COSMIC programs, which d", "url": "https://natlawreview.com/press-releases/mreo-stockholders-have-opportunity-lead-mereo-biopharma-group-plc-class", "source_name": "The National Law Review", "published_at": "2026-06-30T17:10:40", "published_display": "30 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Mereo BioPharma Group plc (MREO) Investors to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Mereo BioPharma Group plc (NASDAQ:MREO) investors following a significant stock price drop. This drop occurred after Mereo announced that two Phase 3 studies for its treatment, setrusumab, failed to", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-mereo-biopharma-group-plc-mreo", "source_name": "The National Law Review", "published_at": "2026-06-27T15:11:14", "published_display": "27 Jun 2026 15:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Mereo BioPharma Group plc \u2013 NASDAQ:MREO", "summary": "This article provides financial data for Mereo BioPharma Group plc (NASDAQ: MREO), specifically focusing on its enterprise value to EBIT forward. The content is presented within the context of TradingView's platform, offering an overview of the company's financial metrics. Howeve", "url": "https://www.tradingview.com/symbols/NASDAQ-MREO/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:38:56", "published_display": "27 Jun 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Mereo BioPharma Group plc \u2013 NASDAQ:MREO", "summary": "This article focuses on the \"Price to book forward\" metric for Mereo BioPharma Group plc, traded under the ticker NASDAQ:MREO. It appears to be a stub or a section of a larger financial data presentation from TradingView, indicating specific financial metrics for the company. The", "url": "https://www.tradingview.com/symbols/NASDAQ-MREO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T07:40:53", "published_display": "26 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Mereo BioPharma Group plc \u2013 NASDAQ:MREO", "summary": "The article focuses on the \"Price to earnings forward\" metric for Mereo BioPharma Group plc (NASDAQ: MREO). It notes that the market is currently closed with no trades, and the content primarily comprises extraneous website navigation and copyright information for TradingView and", "url": "https://www.tradingview.com/symbols/NASDAQ-MREO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T06:11:12", "published_display": "25 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC (MREO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Mereo BioPharma Group PLC (MREO), assessing its profitability and balance sheet. The company has a robust financial status with a score of 7.61, ranking 100 out of 389 in its industry, although its operating efficiency is noted as low", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mreo/financial-health", "source_name": "TradingKey", "published_at": "2026-06-22T12:10:40", "published_display": "22 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC (MREO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Mereo BioPharma Group PLC (MREO), indicating its current valuation score is 7.17 within the Biotechnology & Medical Research industry. It details the company's valuation metrics, including a P/E ratio of -1.39, while noting that relev", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mreo/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:41", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC (MREO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Mereo BioPharma Group PLC (MREO), detailing its current price momentum score, support and resistance levels, and indicator readings. It includes signals from various technical indicators like MACD, RSI, and moving averages, suggesting", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mreo/technical", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:41", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC (MREO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Mereo BioPharma Group PLC (MREO), indicating a strong earnings forecast score and a positive analyst rating. It details the average price target, expected revenue for the next quarter, and historical EPS performance. The report highl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mreo/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:41", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC (MREO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Mereo BioPharma Group PLC (MREO). It indicates that Mereo BioPharma has not distributed any dividends over the past five years and has no recorded stock split history. The page also presents current stock pri", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mreo/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T22:11:26", "published_display": "17 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma : to Participate in Fireside Chat at the Jefferies Global Healthcare Conference 2026", "summary": "Mereo BioPharma Group plc will participate in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 4, 2026, featuring CEO Dr. Denise Scots-Knight. The clinical-stage biopharmaceutical company focuses on rare diseases and has product candidates for osteogenes", "url": "https://www.marketscreener.com/news/mereo-biopharma-to-participate-in-fireside-chat-at-the-jefferies-global-healthcare-conference-2026-ce7f5ddfde8ff12d", "source_name": "www.marketscreener.com", "published_at": "2026-06-03T14:47:00", "published_display": "03 Jun 2026 14:47", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MREO - Mereo Biopharma Group Plc ADR Stock Price and Quote", "summary": "This article provides comprehensive financial data and news for Mereo Biopharma Group Plc ADR (MREO), including its latest stock performance, key financial metrics, analyst ratings, and a chronological list of corporate news and press releases. The company is actively developing ", "url": "https://finviz.com/stock?t=MREO", "source_name": "Finviz", "published_at": "2026-05-30T02:39:37", "published_display": "30 May 2026 02:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo Biopharma Group plc Announces Termination of Dr Annalisa Jenkins from Director, Effective May 14, 2026", "summary": "Mereo Biopharma Group plc has announced that Dr. Annalisa Jenkins's appointment as a director was terminated, effective May 14, 2026. This information was reported by S&P Capital IQ. The company's stock, MREO, saw a minor dip of 0.29% on the day of the announcement, though it had", "url": "https://www.marketscreener.com/news/mereo-biopharma-group-plc-announces-termination-of-dr-annalisa-jenkins-from-director-effective-may-ce7f5dd8db8bf125", "source_name": "www.marketscreener.com", "published_at": "2026-05-26T01:09:55", "published_display": "26 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group plc (NASDAQ: MREO) Long Term Investor Alert: Investigation of potential Wrongdoing", "summary": "A law firm has announced an investigation into potential breaches of fiduciary duties by directors and officers of Mereo BioPharma Group plc (NASDAQ: MREO) on behalf of current long-term investors. This follows a lawsuit alleging securities law violations related to overselling t", "url": "https://www.openpr.com/news/4520764/mereo-biopharma-group-plc-nasdaq-mreo-long-term-investor", "source_name": "openPR.com", "published_at": "2026-05-20T20:09:19", "published_display": "20 May 2026 20:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EcoR1, Oleg Nodelman report 8.4% stake in Mereo (MREO)", "summary": "EcoR1 Capital, LLC and Oleg Nodelman have jointly reported an 8.4% beneficial ownership stake in Mereo BioPharma Group plc (MREO) through an amended Schedule 13G/A filing. This includes shared voting and dispositive power over 66,844,275 Ordinary Shares, which are held via Americ", "url": "https://www.stocktitan.net/sec-filings/MREO/schedule-13g-a-mereo-bio-pharma-group-plc-amended-passive-investment--1664f3adff80.html", "source_name": "Stock Titan", "published_at": "2026-05-15T18:26:06", "published_display": "15 May 2026 18:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of America reports 5.1% stake in Mereo BioPharma | MREO SEC Filing - Form SCHEDULE 13G", "summary": "Bank of America Corporation has reported a 5.1% beneficial ownership stake in Mereo BioPharma Group plc (MREO), amounting to 40,976,460 ordinary shares. This disclosure was made via a SCHEDULE 13G SEC filing, indicating shared voting and dispositive power across Bank of America a", "url": "https://www.stocktitan.net/sec-filings/MREO/schedule-13g-mereo-bio-pharma-group-plc-passive-investment-disclosure-9d4596797fee.html", "source_name": "Stock Titan", "published_at": "2026-05-14T18:40:35", "published_display": "14 May 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Shareholders Approve All AGM Resolutions", "summary": "Mereo BioPharma Group plc shareholders approved all proposed resolutions at their Annual General Meeting on May 14, 2026. Key approvals included the 2025 annual report, auditor reappointment, executive pay, director reappointments, and the extension of share issuance authorities ", "url": "https://www.tipranks.com/news/company-announcements/mereo-biopharma-shareholders-approve-all-agm-resolutions", "source_name": "TipRanks", "published_at": "2026-05-14T15:39:13", "published_display": "14 May 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma shareholders approve all resolutions at annual meeting", "summary": "Mereo BioPharma Group plc announced that all resolutions were approved at its 2026 Annual General Meeting of Shareholders. This included the adoption of the annual report, re-appointment of PwC as auditors, approval of directors' remuneration and policy, and the re-appointment of", "url": "https://m.investing.com/news/sec-filings/mereo-biopharma-shareholders-approve-all-resolutions-at-annual-meeting-93CH-4689130?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-14T14:40:35", "published_display": "14 May 2026 14:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma (NASDAQ: MREO) gains investor approval for pay and share issuance powers", "summary": "Mereo BioPharma Group plc shareholders approved all resolutions at their 2026 Annual General Meeting, including the 2025 accounts, re-appointment of auditors PwC, director remuneration reports and policies, and the re-election of three directors. Investors also authorized the dir", "url": "https://www.stocktitan.net/sec-filings/MREO/8-k-mereo-bio-pharma-group-plc-reports-material-event-29498cef632f.html", "source_name": "Stock Titan", "published_at": "2026-05-14T14:39:13", "published_display": "14 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo Biopharma (MREO) Stock News & Updates", "summary": "This page provides news and updates for Mereo Biopharma (MREO), focusing on its rare-disease biopharmaceutical pipeline. Recent reports highlight financial results, clinical trial progress for setrusumab, alvelestat, and vantictumab, including successes in bone mineral density an", "url": "https://www.stocktitan.net/news/MREO/", "source_name": "Stock Titan", "published_at": "2026-05-14T09:10:24", "published_display": "14 May 2026 09:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO", "summary": "Pomerantz LLP has filed a class action lawsuit against Mereo BioPharma Group plc (MREO) on behalf of investors who suffered losses. The lawsuit alleges securities fraud following significant drops in Mereo's ADR price after clinical trial results for UX143 (setrusumab) failed to ", "url": "https://www.easternprogress.com/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-mereo-biopharma/article_9286c583-e440-5c06-bb53-10cc52005108.html", "source_name": "Eastern Progress", "published_at": "2026-05-14T02:10:06", "published_display": "14 May 2026 02:10", "sentiment": "negative", "sentiment_pct": 16, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates", "summary": "Mereo BioPharma reported its first quarter 2026 financial results, highlighting ongoing efforts to advance its rare disease pipeline. The company is engaging with regulatory agencies regarding setrusumab for pediatric osteogenesis imperfecta and seeking partners for alvelestat's ", "url": "https://uk.finance.yahoo.com/news/mereo-biopharma-reports-first-quarter-113000410.html", "source_name": "Market source", "published_at": "2026-05-13T06:40:35", "published_display": "13 May 2026 06:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group Releases Q1 2026 Financial Results", "summary": "Mereo BioPharma Group plc reported a narrower net loss for Q1 2026, posting -$0.01 diluted loss per share and a net loss of $6.7M. This improvement reflects the company's efforts to control expenses while advancing its therapeutic pipeline for rare diseases. Wall Street analysts ", "url": "https://news.alphastreet.com/mereo-biopharma-group-releases-q1-2026-financial-results/", "source_name": "AlphaStreet", "published_at": "2026-05-12T13:40:03", "published_display": "12 May 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group PLC reports results for the quarter ended March 31 - Earnings Summary", "summary": "Mereo BioPharma Group PLC has announced its earnings summary for the quarter that concluded on March 31. The report, briefly detailed by Refinitiv, provides an overview of the company's financial performance during this period.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41P1YY:0-mereo-biopharma-group-plc-reports-results-for-the-quarter-ended-march-31-earnings-summary/", "source_name": "TradingView", "published_at": "2026-05-12T13:40:03", "published_display": "12 May 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group plc 1Q 2026: Net loss $(6.7M), EPS $(0.01) \u2014 10-Q Summary", "summary": "Mereo BioPharma Group plc reported a narrower net loss of $(6.7M) in Q1 2026 compared to $(12.9M) in the prior year, with diluted EPS improving to $(0.01) from $(0.02). The company had no product revenue and is focusing on its late-stage rare disease pipeline, including setrusuma", "url": "https://www.tradingview.com/news/tradingview:6a7df2c439e4b:0-mereo-biopharma-group-plc-1q-2026-net-loss-6-7m-eps-0-01-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-12T12:40:03", "published_display": "12 May 2026 12:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma (NASDAQ: MREO) Q1 2026 loss narrows as setrusumab data mixed", "summary": "Mereo BioPharma announced its Q1 2026 financial results, reporting a narrowed net loss of $6.7 million compared to $12.9 million a year prior, primarily due to reduced general and administrative expenses. While Phase 3 trials for its key drug setrusumab in osteogenesis imperfecta", "url": "https://www.stocktitan.net/sec-filings/MREO/8-k-a-mereo-bio-pharma-group-plc-amends-material-event-report-b18d99062260.html", "source_name": "Stock Titan", "published_at": "2026-05-12T12:40:03", "published_display": "12 May 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma (NASDAQ: MREO) halves Q1 loss and outlines key trial plans", "summary": "Mereo BioPharma reported a narrower net loss of $6.7 million in Q1 2026, down from $12.9 million year-over-year, mainly due to reduced administrative expenses. The company also provided updates on its rare disease pipeline, noting that while setrusumab's Phase 3 trials missed pri", "url": "https://www.stocktitan.net/sec-filings/MREO/8-k-mereo-bio-pharma-group-plc-reports-material-event-80d130133727.html", "source_name": "Stock Titan", "published_at": "2026-05-12T11:40:03", "published_display": "12 May 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Mereo BioPharma Group (NASDAQ:MREO) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNcm5CemI4Tmh2M2Y1R3hpd1VyRmo1MEJPVXdVdnZDaTREZTd3UG5kQ2M4VmNfOGF3b0hFWWVtaGZPMktQSVl4Z0RDMDI2eTZaQk1iMWtnVGluZTlvUnprN0p5ckpveUY1OUJSdzRXZmlhc2VBdmhURTkwckZwMjhtejM3dWtKN3RYckNRbFFLY0NsNzZDOHhOUlJPVktFZnhE?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stockholders Who Lost Money Investing in Mereo BioPharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwJBVV95cUxOcE1Nc1dSbmx5SVhSVUk1U1BFQXlzd2VyRVczZmpMdi1HdmtMY1lJbGNlSk1jS0xMM3JsaUJ3WTlCempoSE5jaEY3WU83ZnFDOG1uMmcxTTdIMHl5TkNhSG9MZnlVUlhabm9nY0ZEMU5BeVpWTEZDbGdNS3g4OWhwaDM5MVE4M09ReGVmUWVpWm9TLXlUZW9KSGxIaWJDdmo5dnhySVM4Vjk0TXl4M1FmQ0QwcDZWX2xWT2FCZmhWOGNKWDdDdG9JdE1ESndFNHRDTjE0SFpTYjA2alJzTUFUOFZDU3d1cGoyMnVvMDA2MGJha2puQzQtNkJ3dXhKOEoyYXp0MEJEMEJjX1hkSzZ4UVNrcTBncHF4dkpmRDRyYUhicmRxWl9nR3pwNFBJcFBFM1hCa1hkUnRzSUxtY29mSldZQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Mereo BioPharma Group (MREO) Valuation After Mixed Setrusumab Phase 3 Results And Cash Runway Update", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-17T08:00:00+00:00", "published_display": "17 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group (MREO) Is Up 74.4% After Mixed Setrusumab Phase 3 Data and Cash Update \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPWUFDdHZfUGN2MFRqSWRmNG5qcFM5Zjc2bkhEOVNJMHJuZlNLbWpLMEl1b1paN3Y4eVBjNGdaWWFYLTBJQlFkc1FpSmFwNmlEWjlBNFNoU1NKZERfTkViX3RSSjkyNnd1djlLTU9ia1dWbGhwWEk2UC15Ty0xTjJ3aw?oc=5", "source_name": "Market source", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Mereo BioPharma (MREO) Is Up 69.9% After Mixed Setrusumab Phase 3 Results And Pipeline Shift", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Mereo BioPharma (MREO) Valuation After Mixed Setrusumab Phase 3 Update And Conference Spotlight", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNbVJIOHJGby05VnhZN2l6d2NvQTZOS2lfV2hpc3lMUE5tU2FTeWNPNEFNekVYbE55SGkzYlpoVUNxOWJDNjVscWRwa3dEQ2dEQlNKUDJ1bkJqTXo5aTR4OXBnZmtURU5ZTlkteXpCMTZ6VXBJdnowS0FnaTdqMVl3M2RkWlpqbmJK?oc=5", "source_name": "Market source", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group (MREO) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE1KRWZzVjJwcW9YdWlPTnRsMFZCYlJIYWJiVmtEY282UjhqZ2RjLUw1Vnk3SEFCMENMV2NxUXM2S0ZDQjhrbUVMcHRwZlFndHpidGtUU3NoWkZLYjlzQjg2X1I3QWpKWmta?oc=5", "source_name": "MarketBeat", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Group Leads The Charge Among 3 Prominent Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOQmI3MG9MQTR6UVJFWWFaWVpUVWloelFpbV9sbklVb1V5ZHV1RmEyTmNCYmtmcEFNRHJnRDNXUko5d0FhZEM3eVNHa0lzc21tNVhpMV9YcVpjWFdpd0hZUk95V1NFdlVZYkxwNVVjQUNZbDJLWlBTZGR4cTFLeXVKSk83R2xFZTA?oc=5", "source_name": "Market source", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma Stock (MREO) Opinions on Failed Phase 3 Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxONWh3MGJUbVBrbEREMzFmS0lsOWZvTUdJQkhESXFjbDlndHFoQ3dBbGZqdEtVNkgyODVMdDJ1ZUtzdlJ1em91SHJYeFY4VWZtVFB3QWxXcFdYQ1BZSEk5a0FLZFRrak9xYkN6Um5fT3h5YlNmOE5xUGpSQWpNZk5lOU9TVkx6ZDk1aDlJSUV5b2tjRDJ5ZGdHU0VmNUM4ZThY?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-30T08:00:00+00:00", "published_display": "30 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mereo BioPharma stock plummets after failed Phase 3 trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPZDRNZjB0eFFfRGlwZ2xPNXIzcHY4dV9BMllZaDJRRjBIQ3VpRU8zdG9DZDI4QnRUM1hYQUpnWHQydEdkQUM2aHpIamhQVGVZVVhncUVYcG1RWWstcW9YbHFJVzY2RXlBaXdCVmxmV0xvZ1JheW91UllJTzVVTE94c1BQTXZZdS1WRGpaRGZoZjBuX1ZRaENNUWY3UndqaS1NUXJPWDkxbXA3NkNEY25jbE5Qa3M0Rk1PaTF6QQ?oc=5", "source_name": "Investing.com", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 49, "sentiment_summary": {"positive": 6, "negative": 7, "neutral": 36, "score": 48, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 74, "events": [{"event": "general", "label": "Market update", "weight": 10.45, "count": 19}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 18}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.3, "count": 6}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 0.34, "latest_week": "2026-07-10", "one_week_move": 0.1, "four_week_move": 9.8, "twelve_week_move": -0.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.857572, "market_dynamics_buy_signal": false, "relative_strength": -73.764905, "fair_value_gap": -85.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.0151, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.1% over one week, +9.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 48, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "TradingKey", "count": 6}, {"label": "TradingView", "count": 6}, {"label": "Stock Titan", "count": 6}, {"label": "simplywall.st", "count": 5}, {"label": "The National Law Review", "count": 2}, {"label": "www.marketscreener.com", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 19}, {"label": "Earnings", "count": 18}, {"label": "Regulatory and legal", "count": 6}, {"label": "Balance sheet", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.1% over one week, +9.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Mereo BioPharma (MREO) Stock Edges Higher as Biotech Names Find Mixed Footing - Bear Pennant"}], "updated_at": "2026-07-16T12:56:53.619186+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}